Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL2 | P10415 | 1/20 | 0.46 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.42 |
| ▸ | IDO1 | P14902 | 1/20 | 0.41 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.41 |
| ▸ | AGXT | P21549 | 2/20 | 0.40 |
| ▸ | KIF11 | P52732 | 2/20 | 0.40 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.39 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.38 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.38 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.37 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.37 |
| ▸ | PRKCI | P41743 | 1/20 | 0.36 |
| ▸ | DHFR | P00374 | 1/20 | 0.36 |
| ▸ | BACE1 | P56817 | 1/20 | 0.36 |
| ▸ | HTR7 | P34969 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1337835 | 0.89 | BCL2 (0.41) | BCL2PTGS2IDO1NISCHAGXT | |
| SCHEMBL25914755 | 0.81 | BCL2 (0.53) | BCL2PTGS2IDO1NISCHAGXT | |
| SCHEMBL29489424 | 0.80 | BCL2 (0.62) | BCL2PTGS2IDO1NISCHAGXT | |
| SCHEMBL5547358 | 0.80 | BCL2 (0.62) | BCL2PTGS2IDO1NISCHAGXT | |
| SCHEMBL24180478 | 0.79 | BCL2 (0.50) | BCL2PTGS2IDO1NISCHAGXT | |
| SCHEMBL19923215 | 0.78 | BCL2 (0.56) | BCL2PTGS2IDO1NISCHAGXT | |
| SCHEMBL9289390 | 0.77 | TAAR1 (0.55) | BCL2PTGS2IDO1NISCHAGXT | |
| SCHEMBL13484318 | 0.77 | MAOA (0.56) | BCL2PTGS2IDO1NISCH | |
| SCHEMBL1337731 | 0.76 | BCL2 (0.59) | BCL2PTGS2IDO1NISCHAGXT | |
| SCHEMBL13197413 | 0.76 | AGXT (0.61) | BCL2PTGS2IDO1NISCHAGXT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9758474-B2 | Immunomodulator and anti-inflammatory compounds | INCOZEN THERAPEUTICS PVT. LTD. (IN) | 2017-09-12 | — | — | US | disclosed |
| US-20140220050-A1 | NOVEL IMMUNOMODULATOR AND ANTI-INFLAMMATORY COMPOUNDS | INCOZEN THERAPEUTICS PVT. LTD. (CH) | 2014-08-07 | — | — | US | disclosed |
| US-20110275603-A1 | NOVEL IMMUNOMODULATOR AND ANTI-INFLAMMATORY COMPOUNDS | RHIZEN PHARMACEUTICALS SA (FR) | 2011-11-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140220050-A1 | NOVEL IMMUNOMODULATOR AND ANTI-INFLAMMATORY COMPOUNDS | DHODH, DLD, DHFR | BCL2 1855/4885PTGS2 62/4885IDO1 108/4885 |
| US-20110275603-A1 | NOVEL IMMUNOMODULATOR AND ANTI-INFLAMMATORY COMPOUNDS | DHODH, DLD, DHFR | BCL2 1855/4885PTGS2 62/4885IDO1 108/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.